叶轮
医学
心源性休克
不利影响
锁骨下动脉
内科学
腋动脉
冲程(发动机)
科克伦图书馆
荟萃分析
心肌梗塞
外科
机械工程
工程类
作者
Jessica Schultz,Sue Duval,Andrew W. Shaffer,Ranjit John,Tamás Alexy,Cindy M. Martin,Rebecca J. Cogswell
出处
期刊:Asaio Journal
[Lippincott Williams & Wilkins]
日期:2021-05-27
卷期号:68 (2): 233-238
被引量:10
标识
DOI:10.1097/mat.0000000000001452
摘要
data around survival and adverse events of cardiogenic shock (CS) patients supported with axillary or subclavian artery 5.0 Impella are presently unavailable. We performed a systematic search of studies reporting the outcomes of axillary or subclavian access 5.0 Impella for refractory CS in PubMed, EMBASE, and the Cochrane Library. The primary outcome was 30-day survival. Secondary outcomes included survival to next therapy and adverse events on support. Proportional meta-analysis was used to pool across studies. Of the 795 potential studies identified, 13 studies were included in the meta-analysis (n = 256 patients). The average age of patients across studies was 56 ± 5 years. Thirty-day survival for the overall cohort was 66% (95% CI: 59-73). Survival to the next therapy was 68% (95% CI: 60-76). The occurrence of adverse events over an average of 13 (95% CI: 12-14) days of support was the following: stroke 5.9%, hemolysis 27%, pump thrombosis 4.4%, limb ischemia 0.1%, major bleeding 5.4%, device malfunction 10.6%, exchange 6.6%, and infection 14%. In this systematic review and meta-analysis, we report survival and adverse event rates of axillary or subclavian access 5.0 Impella for CS. Such summary data can inform clinician decision-making.
科研通智能强力驱动
Strongly Powered by AbleSci AI